In Vitro Activities of DC-159a, a Novel Fluoroquinolone, against Mycobacterium Species | Zendy

Areeya Disratthakit | Zendy; Norio Doi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro Activities of DC-159a, a Novel Fluoroquinolone, against Mycobacterium Species

Author(s) -

Areeya Disratthakit,

Norio Doi

Publication year - 2010

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01545-09

Subject(s) - in vitro , microbiology and biotechnology , mycobacterium , biology , antibacterial agent , bacteria , antibiotics , genetics

The in vitro activities of DC-159a against seven species of Mycobacterium were compared with moxifloxacin, gatifloxacin, levofloxacin, and rifampin. DC-159a was the most active compound against quinolone-resistant multidrug-resistant M. tuberculosis (MIC(90), 0.5 microg/ml) as well as drug-susceptible isolates (MIC(90), 0.06 microg/ml). The anti-tubercle bacilli activity of DC-159a was 4- to 32-fold more potent than those of currently available quinolones. DC-159a also demonstrated the highest activities against clinically important nontuberculous mycobacteria.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research